The influence of left ventricular ejection fraction on the effectiveness of cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).

An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J (2013) 1.45

Noninvasive Measures of Ventricular-Arterial Coupling and Circumferential Strain Predict Cancer Therapeutics-Related Cardiac Dysfunction. JACC Cardiovasc Imaging (2016) 0.86

Device therapy in heart failure: has CRT changed "the sickest benefit the most" to "the healthiest benefit the most?". J Am Coll Cardiol (2013) 0.85

Effect of cardiac resynchronization therapy with implantable cardioverter defibrillator versus cardiac resynchronization therapy with pacemaker on mortality in heart failure patients: results of a high-volume, single-centre experience. Eur J Heart Fail (2014) 0.78

What is the lowest value of left ventricular baseline ejection fraction that predicts response to cardiac resynchronization therapy? Med Sci Monit (2014) 0.78

Effect of obesity on the effectiveness of cardiac resynchronization to reduce the risk of first and recurrent ventricular tachyarrhythmia events. Cardiovasc Diabetol (2016) 0.77

Defining the real-world reproducibility of visual grading of left ventricular function and visual estimation of left ventricular ejection fraction: impact of image quality, experience and accreditation. Int J Cardiovasc Imaging (2015) 0.76

One-point carotid wave intensity predicts cardiac mortality in patients with congestive heart failure and reduced ejection fraction. Int J Cardiovasc Imaging (2015) 0.76

Cardiac Resynchronisation Therapy: The Optimal QRS Duration Revisited. Arrhythm Electrophysiol Rev (2016) 0.75

Serum phosphate levels reflect responses to cardiac resynchronization therapy in chronic heart failure patients. J Arrhythm (2014) 0.75

A Critical Reappraisal of the Current Clinical Indications to Cardiac Resynchronisation Therapy. Arrhythm Electrophysiol Rev (2013) 0.75

Left ventricular ejection fraction as therapeutic target: is it the ideal marker? Heart Fail Rev (2017) 0.75

Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure. Heart Fail Rev (2016) 0.75

Effect of periodic pacemaker optimization on left atrial reverse remodeling in long-term cardiac resynchronization therapy. J Interv Card Electrophysiol (2013) 0.75

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32

Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med (2002) 27.55

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12

Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation (2006) 9.44

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med (2012) 8.84

Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62

Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation (2010) 6.71

Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 5.95

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol (2006) 5.81

Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med (2006) 5.39

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27

Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67

Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. J Am Coll Cardiol (2008) 4.63

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation (2004) 4.56

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Eur Heart J (2010) 4.13

Long QT syndrome. J Am Coll Cardiol (2008) 4.08

Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80

Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation (2004) 3.78

Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol (2008) 3.73

The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36

Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation (2002) 3.20

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace (2006) 3.11

Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHHS study. Am J Respir Crit Care Med (2013) 3.09

Surgical treatment of atrial fibrillation; a systematic review. Eur J Cardiothorac Surg (2005) 3.06

Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol (2003) 3.05

Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. Circulation (2004) 3.03

Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93

Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA (2013) 2.88

Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation (2007) 2.88

Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. Mol Ther (2006) 2.85

Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. J Am Coll Cardiol (2011) 2.84

Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation (2010) 2.83

Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82

Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79

Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73

Impact of carvedilol and metoprolol on inappropriate implantable cardioverter-defibrillator therapy: the MADIT-CRT trial (Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy). J Am Coll Cardiol (2013) 2.68

Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J (2009) 2.68

Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation (2002) 2.65

Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65

Use of a wearable defibrillator in terminating tachyarrhythmias in patients at high risk for sudden death: results of the WEARIT/BIROAD. Pacing Clin Electrophysiol (2004) 2.63

Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation (2004) 2.63

Echocardiographic findings in patients meeting task force criteria for arrhythmogenic right ventricular dysplasia: new insights from the multidisciplinary study of right ventricular dysplasia. J Am Coll Cardiol (2005) 2.62

Investigation of a novel algorithm for synchronized left-ventricular pacing and ambulatory optimization of cardiac resynchronization therapy: results of the adaptive CRT trial. Heart Rhythm (2012) 2.60

Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation (2011) 2.56

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J (2006) 2.54

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. Circulation (2010) 2.49

Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J (2008) 2.47

Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42

Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation (2007) 2.41

Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2010) 2.41

The influence of public reporting of outcome data on medical decision making by physicians. Arch Intern Med (2005) 2.40

Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40

Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol (2008) 2.39

Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol (2006) 2.32